Dexpoten Plus100 ml

Dexpoten Plus is indicated for the temporary symptomatic relief of cough and upper respiratory symptoms associated with the common cold, upper respiratory tract infections, sinusitis, and allergic rhinitis, including:

• Established/labeled use: Relief of dry, non-productive cough due to minor throat and bronchial irritation (dextromethorphan component).
• Established/labeled use: Temporary relief of nasal and sinus congestion due to the common cold, hay fever, or other upper respiratory allergies (phenylephrine component).
• Established/labeled use: Relief of runny nose, sneezing, and itchy/watery eyes associated with allergic rhinitis or the common cold (triprolidine component).

Dexpoten Plus treats symptoms only and does not treat the underlying cause of cough or cold (e.g., viral infection, bacterial sinusitis, asthma). It is not indicated for chronic cough associated with asthma, emphysema, or smoking, or for a cough accompanied by excessive phlegm (productive cough), unless directed by a physician.

Dextromethorphan + Phenylephrine + Triprolidine is a fixed-dose combination oral preparation (syrup/tablet, depending on manufacturer) containing three active ingredients:

• Dextromethorphan hydrobromide — antitussive (cough suppressant)
• Phenylephrine hydrochloride — nasal decongestant
• Triprolidine hydrochloride — first-generation sedating antihistamine

Exact strength of each component per tablet or per 5 mL of syrup varies by manufacturer and market formulation; always check the product label/carton for the precise strength before use.

Dexpoten Plus is a combination medicine widely used for short-term symptomatic relief of common cold and upper respiratory allergy symptoms. It combines an antitussive, a decongestant, and an antihistamine so that a single preparation addresses cough, nasal/sinus congestion, and allergic symptoms such as sneezing and runny nose together.

It is intended for short-term, symptomatic use and does not cure or shorten the course of the underlying cold or infection.

Dexpoten Plus belongs to the therapeutic class of cough and cold combination preparations, combining an antitussive, an alpha-adrenergic nasal decongestant, and a first-generation (sedating) antihistamine.

Dextromethorphan + Phenylephrine + Triprolidine combines three agents that act by different but complementary mechanisms:

• Dextromethorphan is a centrally acting antitussive that acts on the cough center in the medulla, likely via NMDA-receptor antagonism and sigma-1 receptor agonism, raising the threshold for the cough reflex without significant analgesic or respiratory-depressant effect at therapeutic doses.
• Phenylephrine is a direct-acting, selective alpha-1 adrenergic receptor agonist. It causes vasoconstriction of the dilated blood vessels of the nasal mucosa, reducing tissue edema and nasal/sinus congestion.
• Triprolidine is a first-generation H1-receptor antagonist that competitively blocks histamine at H1 receptors, reducing sneezing, rhinorrhea, and itching; it also has anticholinergic and CNS-depressant (sedating) properties.

Following oral administration, all three components are absorbed from the gastrointestinal tract. Dextromethorphan undergoes extensive hepatic first-pass metabolism, chiefly via CYP2D6, to its active metabolite dextrorphan. Phenylephrine also undergoes significant first-pass metabolism. Triprolidine is metabolized hepatically with a relatively short elimination half-life. All three are eliminated primarily via the kidneys as metabolites.

Dexpoten Plus is for oral use only.

• Shake the syrup well before use and measure the dose using the calibrated measuring cup/spoon provided; do not use household spoons.
• May be taken with or without food; taking with food may reduce stomach upset.
• Swallow tablets whole with water unless the product is scored/chewable per its label.
• Avoid taking at the same time as alcohol or other sedating medicines because of additive drowsiness.
• Do not take a double dose to make up for a missed one.

Dexpoten Plus has the following clinically significant drug interactions:

• Monoamine oxidase inhibitors (MAOIs): Concurrent use, or use within 14 days of stopping an MAOI, can precipitate a hypertensive crisis (via the phenylephrine component) and serotonin syndrome (via the dextromethorphan component). This combination is contraindicated (see Contraindications).
• Serotonergic drugs (e.g., SSRIs, SNRIs, other serotonergic agents): Increased risk of serotonin syndrome with the dextromethorphan component; use with caution.
• CNS depressants (alcohol, sedatives, hypnotics, opioids, other antihistamines): Additive sedation and psychomotor impairment with the triprolidine component; avoid combined use, especially before driving or operating machinery.
• Other sympathomimetic agents/decongestants: Additive cardiovascular stimulant effects (increased blood pressure, heart rate) with the phenylephrine component.
• Antihypertensives and beta-blockers: Phenylephrine may reduce the antihypertensive effect or cause exaggerated pressor response.
• Other anticholinergic drugs: Additive anticholinergic effects (dry mouth, blurred vision, urinary retention) with the triprolidine component.

Side effects of Dexpoten Plus arise from its three components and may include:

• Common: Drowsiness/sedation, dizziness, dry mouth and throat, blurred vision, thickening of bronchial secretions, nausea, stomach upset, restlessness (occasionally paradoxical excitability in children), headache.
• Less common: Palpitations, tachycardia, mild elevation of blood pressure, difficulty urinating, constipation, insomnia, nervousness or tremor.
• Rare/serious: Hallucinations or confusion (especially with dextromethorphan misuse or overdose), serotonin syndrome, severe hypertensive episodes, cardiac arrhythmias, seizures, severe allergic reactions (rash, swelling, difficulty breathing).

Patients should seek medical attention promptly if serious or persistent side effects occur.

Pregnancy: Data on the use of Dexpoten Plus in pregnancy are limited. As with most cold/cough combination products, Dexpoten Plus should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Phenylephrine, being a vasoconstrictor, has a theoretical potential to reduce placental blood flow and should be used cautiously, especially in the first trimester. A physician should be consulted before use in pregnancy.

Lactation: The components of Dexpoten Plus may pass into breast milk in small amounts. Triprolidine (a sedating antihistamine) may cause drowsiness or irritability in a breastfed infant, and antihistamines may also reduce milk supply. Use during breastfeeding should occur only under medical advice, weighing benefits against potential risk to the infant.

Use Dexpoten Plus with caution in the following situations:

• Cardiovascular disease, hypertension, diabetes mellitus, or hyperthyroidism: The phenylephrine component can raise blood pressure and heart rate.
• Narrow-angle glaucoma, symptomatic benign prostatic hyperplasia (BPH), or urinary retention: The anticholinergic effects of the triprolidine component may worsen these conditions; consult a physician before use.
• Asthma, chronic bronchitis, COPD, or productive (phlegm-producing) cough: Suppressing cough or thickening secretions may be inappropriate; medical advice should be sought.
• Sedation: The triprolidine component can cause marked drowsiness. Avoid driving, operating machinery, or drinking alcohol while taking this medicine.
• Hepatic or renal impairment: Use with caution; dose reduction may be needed as elimination of the components may be reduced.
• Elderly patients: More susceptible to anticholinergic and sedative effects (confusion, dizziness, urinary retention); use the lowest effective dose.
• Discontinue and consult a physician if cough persists for more than 7 days, recurs, or is accompanied by fever, rash, or persistent headache, as these may indicate a condition requiring different treatment.
• Not recommended for use in children under 4–6 years except on specific medical advice (see Pediatric Uses).

Overdose of Dexpoten Plus can be serious, particularly in children, and may cause central nervous system depression (drowsiness, lethargy) or, paradoxically, CNS stimulation (excitability, tremor, hallucinations, seizures), severe hypertension, cardiac arrhythmias, respiratory depression, and anticholinergic toxicity (dilated pupils, dry flushed skin, urinary retention, hyperthermia).

If overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt to treat an overdose at home; supportive and symptomatic treatment should be provided under medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Renal impairment: Use Dexpoten Plus with caution; reduced clearance of components may increase risk of adverse effects.
• Hepatic impairment: Use with caution, as hepatic metabolism of dextromethorphan, phenylephrine, and triprolidine may be reduced.
• Elderly: Increased sensitivity to sedative and anticholinergic effects; use the lowest effective dose and monitor closely.
• Children: See Pediatric Uses for age-specific restrictions.
• Pregnant and breastfeeding women: See Pregnancy and Lactation.

Dexpoten Plus is intended for short-term symptomatic use only, generally not exceeding 7 days. If symptoms persist beyond 7 days, worsen, or are accompanied by fever, rash, or persistent headache, discontinue use and consult a physician.

Antitussive + Alpha-adrenergic nasal decongestant + First-generation (sedating) antihistamine (combination)

Dextromethorphan + Phenylephrine + Triprolidine works through three complementary mechanisms: dextromethorphan suppresses the cough reflex by acting centrally on the cough center in the medulla; phenylephrine constricts dilated nasal blood vessels via alpha-1 adrenergic stimulation, relieving nasal/sinus congestion; and triprolidine blocks histamine H1 receptors to reduce sneezing, itching, and rhinorrhea, while also contributing anticholinergic and sedative effects.

Dexpoten Plus is contraindicated in children under 2 years of age due to reports of serious, life-threatening adverse effects associated with cough and cold combination medicines in this age group.

Consistent with FDA/manufacturer voluntary labeling guidance on cough and cold combination products, Dexpoten Plus is not recommended for children under 4–6 years unless specifically directed by a physician, given the risk of serious side effects and the lack of demonstrated benefit in this age group.

For children 6 years and older, use only under medical advice at reduced, age-appropriate doses (see Dosage and Administration). Safety and efficacy in children have not been established to the same standard as in adults, and the lowest effective dose for the shortest necessary duration should be used.